Enterprise Value

6.559B

Cash

647.9M

Avg Qtr Burn

-103.8M

Short % of Float

7.30%

Insider Ownership

0.89%

Institutional Own.

-

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
AYVAKIT (avapritinib) Details
PDGFRA mutant GIST (Gastrointestinal Stromal Tumors)

Approved

Quarterly sales

GAVRETO (parlsetinib) Details
Non-small cell lung carcinoma, Thyroid cancer, Cancer, Solid tumor/s

Approved

Quarterly sales

Approved

Quarterly sales

BLU-945 +/- osimertinib Details
Cancer, Solid tumor/s, Non-small cell lung carcinoma

Phase 1/2

Update

BLU-222 (CDK12) Details
Breast cancer, Cancer

Phase 1/2

Update

BLU-451 Details
Non-small cell lung carcinoma, Cancer, Solid tumor/s

Phase 1/2

Update

Elenestinib Details
Systemic Mastocytosis

Phase 1

Data readout